Int'l Center for Indigenous Phytotherapy Studies--TICIPS

描述（由申请人提供）：密苏里-哥伦比亚大学（MU）将与南非西开普大学（UWC）和圣路易斯密苏里州植物园（MOBOT）合作成立国际土著植物疗法研究中心（TICIPS）。MU在医疗保健质量改善和生物医学科学方面拥有出色的研究和教育计划，包括MU植物营养素和植物化学研究中心。UWC拥有杰出的CAM研究和教育计划，特别是在药用植物方面，并与使用传统治疗师的南非人以及南非政府建立了广泛的联系。MOBOT是北美非洲植物群研究中心。寻求资金的规划工作，建立在MU和UWC之间的17年的关系，以确定TICIPS的使命，愿景和战略计划;发展行政基础设施，以支持合作研究和联合教育活动;并评估所需的资源和建立一个全面的国际中心，研究补充和替代医学的需求。在第一阶段，将建立健全的行政结构和政策，以确保遵守两国关于人类和动物受试者研究、财务披露、利益冲突和知识产权的法规。试点项目将展示合作伙伴的能力，并启动实现NCCAM目标的研究和培训工作。试点1将开启一项关于Sutherlandia frutscens的I期临床试验，Sutherlandia frutscens是一种用于阻止艾滋病患者消瘦的草药。试点2将研究Tulbaghia violacea作为念珠菌病的本土植物疗法。试点3将评估Hypoxis hemerocallidea植物疗法用于前列腺增生和癌症。这些项目的规划和执行以及行政核心的发展将为国际研究和补充及替代医学中心奠定基础。

DESCRIPTION (provided by applicant): The University of Missouri-Columbia (MU) will form the International Center for Indigenous Phytotherapy Studies (TICIPS) in collaboration with the University of Western Cape, South Africa (UWC) and the Missouri Botanical Garden, St. Louis (MOBOT). MU has outstanding research and educational programs in health care quality improvement and biomedical sciences, including the MU Center for Phytonutrient and Phytochemical Studies. UWC has outstanding CAM research and educational programs, especially in medicinal plants, and extensive ties with South Africans that use traditional healers, and with the South African government. MOBOT is the North American center for research of African flora. Funds are sought for a planning effort, building upon a 17-year relationship between MU and UWC, to define the mission, vision and strategic plan for TICIPS; to develop the administrative infrastructure to support collaborative research studies and joint educational activities; and to assess resources and needs required for the establishment of a comprehensive international center for research on complementary and alternative medicine. During Phase I, sound administrative structures and policies will be established to ensure compliance with both countries' regulations on the conduct of research with human subjects and animal subjects, financial disclosure, conflict of interest and intellectual property rights. The pilots will serve to demonstrate the capabilities of the partners and to initiate research and training efforts that fulfill the goals of NCCAM. Pilot 1 will open a Phase I clinical trial on Sutherlandia frutscens, an herbal used to deter wasting in AIDS patients. Pilot 2 will study Tulbaghia violacea as an indigenous phytotherapy for candidiasis. Pilot 3 will evaluate Hypoxis hemerocallidea phytotherapies for prostate hyperplasia and cancer. Planning and execution of these projects and the development of an administrative core will lay the foundation for an International Center for Research and Complementary and Alternative Medicine.